SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

SITC 2023: FIERCE-HN: A multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/ recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

CCS 2023: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients with cachexia and elevated GDF-15 levels

ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI

ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI

ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab

ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab

ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial

ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI

ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI

ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

ASCO GI 2022: A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers

ASCO GI 2022: A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers

ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE

ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE